The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.
Also called NCT07925359
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT07925359
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Croatia, Czechia, France
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07925359. Allocation not applicable; no masking; primary purpose treatment. Start 2027-01-20 (anticipated); primary completion 2027-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation
- Acronym
- NAVigate-ULTRA
- Condition
- Atrial Fibrillation (AF)
- Condition
- Paroxysmal AF
- Condition
- Persistent Atrial Fibrillation (PersAF)
- Condition
- FARAPULSE
- Intervention (Device)
- Ablation Treatment with FARAPULSE™ Pulsed Field Ablation (PFA) System and OPAL HDx™ Mapping System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct07925359- Content hash
abb3ce7cc3922f6ccbca921c089f2dd937390d116eea5c322b564c870c4cc3a8